A combination of sodium phenylbutyrate and taurursodiol has shown tantalising preliminary results against functional decline in patients with amyotrophic lateral sclerosis (ALS). In a 24-week phase 2 randomised controlled trial, US researchers showed that the combination – also known as tauroursodeoxycholic acid – was associated with a 25% drug-associated slowing of the rate of functional ...
Combination therapy shows promising efficacy against ALS decline
By Michael Woodhead
3 Sep 2020